Results from ASTRUM-004: Phase 3 trial of first-line serplulimab plus chemotherapy as treatment for advanced squamous non-small-cell lung cancer
In this medfyle
In this phase 3 trial of previously untreated patients with stage IIIB/IIIC or IV squamous NSCLC without targetable gene alterations, serplulimab plus chemotherapy demonstrated superior efficacy to placebo plus chemotherapy as a first-line treatment, significantly improving PFS and OS, with a manageable safety profile.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article: Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, Wu L, Wang X, Viguro M, Makharadze T, Sun H, Luo F, Shi J, Zang A, Pan Y, Chen Z, Jia Z, Kuchava V, Lu P, Zhang L, Cheng Y, Kang W, Wang Q, Yu H, Li J, Zhu J; ASTRUM-004 Investigators. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell. 2024 Feb 12;42(2):198-208.e3. doi: 10.1016/j.ccell.2023.12.004. Epub 2024 Jan 4. PMID: 38181795.
The summary content was prepared by Rhian Shurlock for Medfyle, and reviewed by Marianna Aita, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
